NEW YORK--(BUSINESS WIRE)--VB Spine LLC (“VB Spineˮ), the largest privately held spine company, today announced the appointment of Thomas E. Oglesby as Chief Financial Officer, effective Sept. 16, 2026. Oglesby joins VB Spine from Zimmer Biomet, where he most recently served as Vice President, Finance for the company's Sports, Extremities and Trauma global business unit.
VB Spine Appoints Thomas E. Oglesby as New Chief Financial Officer
2 min read Premium comments
appointmentVB Spine LLCChief Financial OfficerThomas E Oglesby
In his new role, Oglesby will lead VB Spine's finance organization and partner with the executive team on strategy, capital allocation, and continued growth of the company's spine portfolio.
“Thomasʼs deep spine industry knowledge, hands-on operating experience, and proven track record leading finance through periods of significant growth and transformation make him an excellent fit for this role,ˮ said Anthony Viscogliosi, co-CEO of VB Spine, speaking on behalf of his brothers, Marc and John Viscogliosi. “As we continue to expand our technology and biologics portfolio, his experience will be instrumental in helping us scale VB Spine toward category leadership.ˮ
Oglesby brings more than 20 years of medtech finance experience, including senior roles at Zimmer Biomet and Medtronic. He led finance as Vice President and Business Unit CFO for Zimmer Biomet's Dental and Spine division, stepping in as Interim General Manager of the Spine business during a transition period, and leading the finance workstream through the carve-out and spin-off of ZimVie. Earlier in his career, he served as CFO of Human Care Systems, a privately funded healthcare startup, and held finance and program management roles at Medtronic, including supporting the company's Spine & Navigation business and its acquisition of Kyphon.
“I am excited to join VB Spine at such a pivotal moment in the company's growth,ˮ said Oglesby. “VB Spine's combination of scale, entrepreneurial spirit, and direct ownership involvement is exactly the environment I have been looking for, and Iʼm ready to partner with the team to build on the momentum the company has established. What matters most here is helping surgeons take better care of patients, and that is the work I want to be a part of.ˮ
Oglesby holds an MBA in Finance and a Bachelor of Business Administration in Accounting, both from the University of Memphis.
Forward-Looking Statements
Certain statements in this release are forward-looking and are based on current expectations, forecasts, and assumptions. Actual results may differ materially due to regulatory, commercial, and operational risks. VB Spine disclaims any obligation to update forward-looking statements except as required by law.
About VB Spine
VB Spine LLC is the largest privately held spine company and among the largest family-owned medical technology companies in the world. With a comprehensive portfolio and a large and growing global distribution network, VB Spine delivers specialized solutions that address critical needs in spine surgery and enhance patient outcomes. Focused on people, partnerships, and operational excellence, VB Spine ensures healthcare professionals have access to the tools and resources needed to provide the highest standard of care. VB Spine is owned and led by the Viscogliosi Brothers. For more information on VB Spine, please visit www.vbspineco.com.
Contacts
For media inquiries only:
spinecommunications@vbspineco.com
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
VB Spine, the largest privately held spine company, appointed Thomas E. Oglesby as CFO, effective September 2026. This strategic hire, with Oglesby's extensive background in medtech finance, M&A, and spin-offs from Zimmer Biomet and Medtronic, signals VB Spine's commitment to aggressive growth. His role will focus on capital allocation and expanding their technology and biologics portfolio to achieve category leadership.
- Oglesby's experience in M&A and spin-offs (e.g., ZimVie) is valuable for VB Spine's strategic growth and potential market consolidation.
- His focus on capital allocation and portfolio expansion indicates VB Spine's intent to aggressively compete for category leadership in the spine market.
PhD Lens: Clinical and outcomes impact
VB Spine appointed Thomas E. Oglesby as CFO, effective September 2026. While a finance role, Oglesby's appointment is intended to bolster VB Spine's strategic expansion of its technology and biologics portfolio. This move aims to scale the company's offerings, ultimately supporting the development and distribution of specialized solutions designed to enhance patient outcomes in spine surgery.
- The new CFO's role is positioned to support the strategic expansion of VB Spine's technology and biologics portfolio.
- This financial leadership is intended to facilitate the development and distribution of specialized solutions for spine surgery, aiming to enhance patient outcomes.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.